Scandinavian consumer goods group Orkla has announced that it has acquired the gut health supplement brand Colon-C through an asset transaction, via its wholly owned subsidiary Orkla Health Poland.
Orkla describes Colon-C as a leading brand in the constipation category and a strong market leader in the fibre segment in Poland. By acquiring Colon-C, Orkla will expands its platform in gut health, which already consists of the brands Husk and Samarin, the company added.
Colon-C, which was previously owned by herbal supplement firm A-Z Medica, achieved turnover of 14.6 million PLN ($3.8 million) in 2015.
Commenting on the deal, Orkla Health Group CEO Henning Søgaard said: “The acquisition of Colon-C is strategically important for strengthening Orkla Health’s position in a growing category. Poland is a priority market for Orkla Health, and we have identified potential opportunities for value creation in the form of both increased sales and cost synergies. With close to 75% of sales through pharmacies, the acquisition of Colon-C also strengthens Orkla Health’s presence in the pharmacy channel”.
The transaction does not involve transfer of employees or production sites, Orkla said.